Trastuzumab Deruxtecan in HER2-Low or HER2-Mutant Recurrent/Metastatic Secretory Gland Cancers of the Head and Neck: A Case Series.
Michael T Wotman, Alexander Khalaf, Kaiwen Wang...
https://pubmed.ncbi.nlm.nih.gov/41213241/Actively Recruiting
Led by NRG Oncology · Updated on 2026-10-23
146
Participants Needed
154
Research Sites
260 weeks
Total Duration
This research evaluates targeted therapies for patients with HER2-expressing salivary gland cancer that is recurrent, has spread to other parts of the body, or cannot be removed by surgery. It compares the usual treatment of chemotherapy with docetaxel plus trastuzumab against ado-trastuzumab emtansine T-DM1 in patients with HER2-positive cancer. It also studies how trastuzumab deruxtecan works in patients with HER2-low expressing salivary gland cancer. The study aims to understand which treatment may better control cancer growth and improve survival. Participants are assigned to different treatment groups based on their HER2 status. Those with HER2-positive cancer are randomly assigned to receive either docetaxel plus trastuzumab every 21 days for up to 6 cycles or ado-trastuzumab emtansine every 21 days until progression or toxicity. Patients with HER2-low expressing cancer receive trastuzumab deruxtecan every 21 days. Treatments are given intravenously, and patients may cross over to the other treatment if their disease progresses. Imaging scans, heart function tests, blood samples, and biopsies occur during screening and treatment. Throughout the study, participants undergo regular assessments including CT or MRI scans and heart evaluations to monitor cancer status and treatment effects. Blood samples and biopsies help researchers study the cancers biology. After treatment ends, patients are followed up every 3 months for 2 years, then every 6 months for an additional 3 to 5 years, and then annually to track long-term outcomes. Researchers measure progression-free survival and response rates to evaluate treatment impact.
CONDITIONS
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
NRG Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Ado‑Trastuzumab Emtansine (T‑DM1) | Docetaxel + Trastuzumab | Trastuzumab Deruxtecan (T‑DXd) |
|---|---|---|---|
| What each option is | Antibody‑drug conjugate linking trastuzumab to a cytotoxic agent (emtansine) | Combination of chemotherapy drug docetaxel plus HER2‑targeted antibody trastuzumab | Antibody‑drug conjugate combining trastuzumab with deruxtecan payload |
| Role in trial | Investigational arm evaluating T‑DM1 | Standard active comparator arm | Investigational arm evaluating trastuzumab deruxtecan |
| Primary purpose | Treatment of HER2‑expressing recurrent or metastatic salivary gland carcinoma | Treatment of HER2‑expressing recurrent or metastatic salivary gland carcinoma | Treatment of HER2‑expressing recurrent or metastatic salivary gland carcinoma |
| Administration method | Given intravenously | Both agents given intravenously | Given intravenously |
| Evidence outside this trial | Case reports and small series suggest activity in HER2‑positive salivary gland carcinoma | Used historically based on small series but lacks formal standard; systemic therapy remains understudied | Phase I data show antitumor activity in HER2‑expressing salivary gland carcinoma |
| Key risks | Risks typical of antibody‑drug conjugates and chemotherapy payload | Chemotherapy and antibody safety profile applies (e.g., neutropenia, cardiac effects) | Interstitial lung disease or pneumonitis reported in ADC trials |
| Limitations to consider | Evidence limited to small series and case reports; not yet standard | Limited formal efficacy data for recurrent/metastatic salivary gland carcinoma | Data from early‑phase trials only; sample sizes small |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 6 cycles or until disease progression or unacceptable toxicity
Participants receive one of the study treatments intravenously every 21 days. Those with HER2-positive cancer receive either docetaxel plus trastuzumab for up to 6 cycles or ado-trastuzumab emtansine until disease progression or unacceptable side effects. Those with HER2-low expression receive trastuzumab deruxtecan until progression or toxicity. Imaging and heart tests are done regularly during treatment.
Every 21 days
Duration - Up to 7 years or more
After treatment ends, participants are followed every 3 months for 2 years, then every 6 months for 3 to 5 years, and then annually to monitor health and cancer status.
Every 3 to 6 months, then annually
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Michael T Wotman, Alexander Khalaf, Kaiwen Wang...
https://pubmed.ncbi.nlm.nih.gov/41213241/NRG Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor